Can analysts adopt a bullish outlook for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)?

June 27, 2018 - By Jacob Falcon

Investors sentiment increased to 3 in 2018 Q1. Its up 1.38, from 1.62 in 2017Q4. It is positive, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 6 reduced holdings. 10 funds opened positions while 17 raised stakes. 10.28 million shares or 3.03% more from 9.98 million shares in 2017Q4 were reported.
Hightower Advsr Limited Co has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Jpmorgan Chase And has 59,502 shares for 0% of their portfolio. Royal Fincl Bank Of Canada reported 40 shares stake. Element Management Limited Com holds 0% or 16,431 shares in its portfolio. Fmr Limited Liability reported 1.61 million shares. State Street Corp invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Peddock Advsrs Ltd Co has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 752 shares. Citadel Advisors Ltd Co owns 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 11,250 shares. Geode Capital Mngmt Ltd Liability Corp holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 102,263 shares. Barclays Public Limited Company stated it has 1 shares or 0% of all its holdings. Blackrock holds 39,407 shares or 0% of its portfolio. Stanley holds 64,029 shares. 48,151 were accumulated by Northern Trust. 4,615 are owned by Bankshares Of America De. Bluecrest Cap Mgmt owns 14,371 shares for 0% of their portfolio.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since January 26, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $2300 target in Tuesday, June 26 report. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 15. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 29. Below is a list of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) latest ratings and price target changes.

26/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0000 Maintain
15/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0000 Maintain
29/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0000 Maintain
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $13 Initiates Coverage On

The stock increased 0.29% or $0.02 during the last trading session, reaching $8.5. About 100 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 82.11% since June 27, 2017 and is uptrending. It has outperformed by 69.54% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $170.93 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.